
    
      A multicenter Open-label, single-arm, phase II clinical trial is conducted on patients with
      histological stage IV colorectal cancer given irinotecan plus S-1. The usefulness of this
      regimens as 1st line therapy for colorectal cancer was evaluated by the disease-free survival
      rate (DFR), overall survival rate (OS), incidence and severity of adverse event.
    
  